Alnylam Pharmaceuticals’ investigative patisiran treatment improves overall health and prevents worsening of walking ability in patients with familial amyloid polyneuropathy (FAP), according to a new analysis from the APOLLO Phase 3 study. FAP, also known as hereditary ATTR (hATTR) amyloidosis, is caused by mutations of the transthyretin (TTR) gene…
Familial amyloid polyneuropathy (FAP) patients who do not have a Val30Met mutation exhibit prevalent cardiac and blood vessel dysfunction, but proper blood vessel constriction remains intact, even in patients with advanced nerve damage, a study suggests. The study, “Widespread Cardiac and Vasomotor Autonomic Dysfunction in Non-Val30Met Hereditary…
Treatment with the investigative therapy Tegsedi (inotersen) provides early and significant improvements in neuropathy symptoms and quality of life in patients with familial amyloid polyneuropathy (FAP), according to results from a pivotal Phase 2/3 clinical trial. These results, announced by Ionis Pharmaceuticals, the treatment’s developer, and its affiliate, Akcea…
The European Commission (EC) has approved Tegsedi (inotersen), by Akcea Therapeutics and Ionis Pharmaceuticals, to treat stage 1 or 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (hATTR). The approval — in the form of marketing authorization — comes on the heels of a positive recommendation by the…
A Phase 3 trial testing patisiran as a therapy for hereditary ATTR amyloidosis with polyneuropathy (also called familial amyloid polyneuropathy, or FAP), showed treatment with patisiran safely improved many symptoms as well as patients’ quality of life. The full results have been published in The New England…
Researchers have reported the case of a Portuguese man with late-onset familial amyloid polyneuropathy (FAP) and a rare combination of heart failure with a severe accumulation of fluids in the abdominal cavity. The case report, “Val30Met Familial Amyloid Polyneuropathy, Heart Failure, and Chylous Ascites: An Unexpected…
Treatment with Vyndaqel (tafamidis) or liver transplant can significantly improve the long-term outcome of patients with familial amyloid polyneuropathy (FAP) due to a common TTR mutation, researchers reported. FAP, also known as transthyretin-related hereditary amyloidosis (hATTR), is a rare disease caused by genetic mutations in the…
A series of potential predictors for identifying patients with familial amyloid polyneuropathy (FAP) and distinguishing it from other diseases with similar symptoms, namely chronic inflammatory demyelinating polyneuropathy (CIDP), were recently found through a retrospective analysis. The study, “Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy,” was published in…
Researchers reported a rare case of familial amyloid polyneuropathy (FAP) in a patient with TRR gene Val30Met mutation who was experiencing impaired upper limb sensation and numbness. The case was described in “A Val30Met sporadic familial amyloid polyneuropathy case with atypical presentation: upper limb onset of…
A parameter called electrochemical skin conductance is linked to disease severity in patients with familial amyloid polyneuropathy (FAP), potentially supporting the use of a device called Sudoscan to assess the clinical evolution of the disease, according to researchers. Their study, “The value of electrochemical skin conductance measurement using…